Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc's positive outlook is supported by a 140% growth in Hepzato procedure volume in 2025, indicating increased utilization and commercial adoption by physicians. The company's year-end cash balance increased to $91.0 million, demonstrating operational efficiency and financial stability, which bodes well for future expansion efforts. Furthermore, management's focus on salesforce expansion, along with strong clinical data from the FOCUS trial, is anticipated to drive referral growth and treatment adoption in both existing and new markets.

Bears say

Delcath Systems Inc has recently lowered its full-year revenue expectations to $83M-$85M, down from a prior estimate of $93M-$96M, primarily due to a significant slowdown in new site activations and a decline in average revenue per kit linked to the Medicaid National Drug Rebate Agreement Program. The company faced unexpected summer seasonality and increased competition in clinical trials, leading to a dramatic decrease in new patient starts, which fell by approximately two-thirds per site as a result of scheduling challenges and appointment cancellations. Additionally, the company operates on a cash flow negative basis, raising concerns about its ability to sustain operations and generate forecasted revenues moving forward.

Delcath Systems (DCTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.